Trial Outcomes & Findings for Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833 (NCT NCT02437227)

Last Updated: 2026-05-12

Results Overview

Number of patients with DLT in each cohort/dose level. The maximum tolerated dose is the dose at which no more than one patient out of up to six patients at the same dose level experience a highly probably or probably drug-related DLT as defined in the protocol.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

31 participants

Primary outcome timeframe

Patients were assessed for DLTs from trial treatment start (cycle 1 day 1) through each of the treatment (28 days) cycles until the patients' final safety follow up at 30 days after last dose for up to 18 months.

Results posted on

2026-05-12

Participant Flow

Study opened on 15/04/2015 to recruit 31 patients at two sites (Royal Marsden and Christie).

Participant milestones

Participant milestones
Measure	Experiment - CCT3833 Cohort 1 Part A - Dose escalation stage - Dose level 1 : 20mg	Experiment - CCT3833 Cohort 2 Part A - Dose escalation stage - Dose level 2 : 40mg	Experiment - CCT3833 Cohort 3 Part A - Dose escalation stage - Dose level 3 : 75mg	Experiment - CCT3833 Cohort 4 Part A - Dose escalation stage - Dose level 4 : 150mg	Experiment - CCT3833 Cohort 5 Part A - Dose escalation stage - Dose level 5 : 300mg	Experiment - CCT3833 Cohort 6 Part A - Dose escalation stage - Dose level 6 : 600mg	Experiment - CCT3833 Cohort 7 Part A - Dose escalation stage - Dose level 7 : 900mg	Experiment - CCT3833 Cohort 8 Part A - Dose escalation stage - Dose level 8 : 1350mg
Overall Study STARTED	3	3	3	3	4	6	4	5
Overall Study COMPLETED	3	3	3	3	4	6	4	5
Overall Study NOT COMPLETED	0	0	0	0	0	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Experiment - CCT3833 Cohort 1 n=3 Participants Part A - Dose escalation stage -Dose level 1 : 20mg	Experiment - CCT3833 Cohort 2 n=3 Participants Part A - Dose escalation stage -Dose level 2 : 40mg	Experiment - CCT3833 Cohort 3 n=3 Participants Part A - Dose escalation stage -Dose level 3 : 75mg	Experiment - CCT3833 Cohort 4 n=3 Participants Part A - Dose escalation stage -Dose level 4 : 150mg	Experiment - CCT3833 Cohort 5 n=4 Participants Part A - Dose escalation stage -Dose level 5 : 300mg	Experiment - CCT3833 Cohort 6 n=6 Participants Part A - Dose escalation stage -Dose level 6 : 600mg	Experiment - CCT3833 Cohort 7 n=4 Participants Part A - Dose escalation stage -Dose level 7 : 900mg	Experiment - CCT3833 Cohort 8 n=5 Participants Part A - Dose escalation stage -Dose level 8 : 1350mg	Total n=31 Participants Total of all reporting groups
Age, Continuous	48.84 years STANDARD_DEVIATION 10.50 • n=1512 Participants	58.86 years STANDARD_DEVIATION 14.63 • n=504 Participants	66.40 years STANDARD_DEVIATION 9.76 • n=2016 Participants	61.80 years STANDARD_DEVIATION 3.54 • n=99 Participants	56.51 years STANDARD_DEVIATION 2.12 • n=97 Participants	49.15 years STANDARD_DEVIATION 8.75 • n=488 Participants	60.64 years STANDARD_DEVIATION 15.83 • n=70 Participants	46.30 years STANDARD_DEVIATION 13.25 • n=40 Participants	54.93 years STANDARD_DEVIATION 11.72 • n=295 Participants
Sex: Female, Male Female	1 Participants n=1512 Participants	1 Participants n=504 Participants	2 Participants n=2016 Participants	1 Participants n=99 Participants	0 Participants n=97 Participants	5 Participants n=488 Participants	2 Participants n=70 Participants	3 Participants n=40 Participants	15 Participants n=295 Participants
Sex: Female, Male Male	2 Participants n=1512 Participants	2 Participants n=504 Participants	1 Participants n=2016 Participants	2 Participants n=99 Participants	4 Participants n=97 Participants	1 Participants n=488 Participants	2 Participants n=70 Participants	2 Participants n=40 Participants	16 Participants n=295 Participants
Race/Ethnicity, Customized Ethnicity · African/Caribbean	0 Participants n=1512 Participants	0 Participants n=504 Participants	0 Participants n=2016 Participants	1 Participants n=99 Participants	0 Participants n=97 Participants	0 Participants n=488 Participants	0 Participants n=70 Participants	0 Participants n=40 Participants	1 Participants n=295 Participants
Race/Ethnicity, Customized Ethnicity · Caucasian	3 Participants n=1512 Participants	3 Participants n=504 Participants	3 Participants n=2016 Participants	2 Participants n=99 Participants	4 Participants n=97 Participants	6 Participants n=488 Participants	4 Participants n=70 Participants	5 Participants n=40 Participants	30 Participants n=295 Participants
Region of Enrollment United Kingdom	3 participants n=1512 Participants	3 participants n=504 Participants	3 participants n=2016 Participants	3 participants n=99 Participants	4 participants n=97 Participants	6 participants n=488 Participants	4 participants n=70 Participants	5 participants n=40 Participants	31 participants n=295 Participants

PRIMARY outcome

Timeframe: Patients were assessed for DLTs from trial treatment start (cycle 1 day 1) through each of the treatment (28 days) cycles until the patients' final safety follow up at 30 days after last dose for up to 18 months.

Population: Intention to treat (ITT) population. Patients were enrolled and treated in the Part A dose escalation stage only.

Outcome measures

Outcome measures
Measure	Experiment - CCT3833 Cohort 1 n=3 Participants Part A - Dose escalation stage - Dose level 1: 20mg	Experiment - CCT3833 Cohort 2 n=3 Participants Part A - Dose escalation stage - Dose level 2: 40mg	Experiment - CCT3833 Cohort 3 n=3 Participants Part A - Dose escalation stage - Dose level 3: 75mg	Experiment - CCT3833 Cohort 4 n=3 Participants Part A - Dose escalation stage - Dose level 4: 150mg	Experiment - CCT3833 Cohort 5 n=4 Participants Part A - Dose escalation stage - Dose level 5: 300mg	Experiment - CCT3833 Cohort 6 n=6 Participants Part A - Dose escalation stage - Dose level 6: 600mg	Experiment - CCT3833 Cohort 7 n=4 Participants Part A - Dose escalation stage - Dose level 7: 900mg	Experiment - CCR3833 Cohort 8 n=5 Participants Part A - Dose escalation stage - Dose level 8: 1350mg
Number and Percentage of Patients With Dose Limiting Toxicities (DLT).	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants

PRIMARY outcome

Timeframe: AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose for up to 18 months.

Population: Intention to treat (ITT) all patients recruited and stated treatment.

Determining causality of each adverse event (AE) to CCT3833 and grade according to National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Outcome measures

Outcome measures
Measure	Experiment - CCT3833 Cohort 1 n=3 Participants Part A - Dose escalation stage - Dose level 1: 20mg	Experiment - CCT3833 Cohort 2 n=3 Participants Part A - Dose escalation stage - Dose level 2: 40mg	Experiment - CCT3833 Cohort 3 n=3 Participants Part A - Dose escalation stage - Dose level 3: 75mg	Experiment - CCT3833 Cohort 4 n=3 Participants Part A - Dose escalation stage - Dose level 4: 150mg	Experiment - CCT3833 Cohort 5 n=4 Participants Part A - Dose escalation stage - Dose level 5: 300mg	Experiment - CCT3833 Cohort 6 n=6 Participants Part A - Dose escalation stage - Dose level 6: 600mg	Experiment - CCT3833 Cohort 7 n=4 Participants Part A - Dose escalation stage - Dose level 7: 900mg	Experiment - CCR3833 Cohort 8 n=5 Participants Part A - Dose escalation stage - Dose level 8: 1350mg
Assessing the Safety and Tolerability Profile of CCT3833. (Adverse Event) Patients with any toxicities grade 3 and above	1 Participants	2 Participants	2 Participants	1 Participants	2 Participants	4 Participants	2 Participants	4 Participants
Assessing the Safety and Tolerability Profile of CCT3833. (Adverse Event) Patients with any toxicities grade 1 and above	3 Participants	3 Participants	3 Participants	3 Participants	4 Participants	6 Participants	4 Participants	5 Participants

Adverse Events

Experiment - CCT3833 Cohort 1

Serious events: 2 serious events

Other events: 3 other events

Deaths: 3 deaths

Experiment - CCT3833 Cohort 2

Serious events: 3 serious events

Other events: 3 other events

Deaths: 3 deaths

Experiment - CCT3833 Cohort 3

Serious events: 1 serious events

Other events: 3 other events

Deaths: 2 deaths

Experiment - CCT3833 Cohort 4

Serious events: 0 serious events

Other events: 3 other events

Deaths: 3 deaths

Experiment - CCT3833 Cohort 5

Serious events: 0 serious events

Other events: 4 other events

Deaths: 4 deaths

Experiment - CCT3833 Cohort 6

Serious events: 2 serious events

Other events: 6 other events

Deaths: 5 deaths

Experiment - CCT3833 Cohort 7

Serious events: 2 serious events

Other events: 4 other events

Deaths: 3 deaths

Experiment - CCT3833 Cohort 8

Serious events: 3 serious events

Other events: 5 other events

Deaths: 4 deaths

Serious adverse events

Serious adverse events
Measure	Experiment - CCT3833 Cohort 1 n=3 participants at risk Part A - Dose escalation stage: Dose level 1: 20mg	Experiment - CCT3833 Cohort 2 n=3 participants at risk Part A - Dose escalation stage: Dose level 2: 40mg	Experiment - CCT3833 Cohort 3 n=3 participants at risk Part A - Dose escalation stage: Dose level 3: 75mg	Experiment - CCT3833 Cohort 4 n=3 participants at risk Part A - Dose escalation stage: Dose level 4: 150mg	Experiment - CCT3833 Cohort 5 n=4 participants at risk Part A - Dose escalation stage: Dose level 5: 300mg	Experiment - CCT3833 Cohort 6 n=6 participants at risk Part A - Dose escalation stage: Dose level 6: 600mg	Experiment - CCT3833 Cohort 7 n=4 participants at risk Part A - Dose escalation stage: Dose level 7: 900mg	Experiment - CCT3833 Cohort 8 n=5 participants at risk Part A - Dose escalation stage: Dose level 8: 1350mg
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Colonic obstruction	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Gastritis	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Nausea	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Vomiting	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
General disorders Fever	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Hepatobiliary disorders Cholecystitis	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Infections and infestations Lung infection	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Injury, poisoning and procedural complications Fracture	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Metabolism and nutrition disorders Hypocalcemia	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Nervous system disorders Dysphasia	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 2/6 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Nervous system disorders Headache	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Respiratory, thoracic and mediastinal disorders Dyspnea	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Musculoskeletal and connective tissue disorders Other	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Blood and lymphatic system disorders Other	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.

Other adverse events

Other adverse events
Measure	Experiment - CCT3833 Cohort 1 n=3 participants at risk Part A - Dose escalation stage: Dose level 1: 20mg	Experiment - CCT3833 Cohort 2 n=3 participants at risk Part A - Dose escalation stage: Dose level 2: 40mg	Experiment - CCT3833 Cohort 3 n=3 participants at risk Part A - Dose escalation stage: Dose level 3: 75mg	Experiment - CCT3833 Cohort 4 n=3 participants at risk Part A - Dose escalation stage: Dose level 4: 150mg	Experiment - CCT3833 Cohort 5 n=4 participants at risk Part A - Dose escalation stage: Dose level 5: 300mg	Experiment - CCT3833 Cohort 6 n=6 participants at risk Part A - Dose escalation stage: Dose level 6: 600mg	Experiment - CCT3833 Cohort 7 n=4 participants at risk Part A - Dose escalation stage: Dose level 7: 900mg	Experiment - CCT3833 Cohort 8 n=5 participants at risk Part A - Dose escalation stage: Dose level 8: 1350mg
Blood and lymphatic system disorders Anemia	33.3% 1/3 • Number of events 6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	66.7% 2/3 • Number of events 5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Blood and lymphatic system disorders Lymph node pain	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Abdominal pain	100.0% 3/3 • Number of events 6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	50.0% 2/4 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	50.0% 3/6 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	80.0% 4/5 • Number of events 8 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Bloating	66.7% 2/3 • Number of events 5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 10 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Constipation	66.7% 2/3 • Number of events 5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	66.7% 2/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 2/6 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	50.0% 2/4 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	60.0% 3/5 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Diarrhea	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	66.7% 2/3 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	50.0% 3/6 • Number of events 14 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Dry mouth	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	40.0% 2/5 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Gastrointestinal pain	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	66.7% 2/3 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Mucositis oral	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Nausea	66.7% 2/3 • Number of events 7 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	66.7% 4/6 • Number of events 7 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	75.0% 3/4 • Number of events 18 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	40.0% 2/5 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Gastrointestinal disorders Vomiting	66.7% 2/3 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 2/6 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	50.0% 2/4 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
General disorders Edema limbs	66.7% 2/3 • Number of events 5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
General disorders Fatigue	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	66.7% 2/3 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	66.7% 2/3 • Number of events 9 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	50.0% 2/4 • Number of events 6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	60.0% 3/5 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
General disorders Fever	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	40.0% 2/5 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
General disorders Pain	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Infections and infestations Lung infection	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	50.0% 2/4 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Respiratory, thoracic and mediastinal disorders Upper respiratory infection	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Infections and infestations Urinary tract infection	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	66.7% 2/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Investigations Alanine aminotransferase increased	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	50.0% 2/4 • Number of events 6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	75.0% 3/4 • Number of events 11 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	80.0% 4/5 • Number of events 12 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Investigations Alkaline phosphatase increased	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	50.0% 2/4 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Investigations Aspartate aminotransferase increased	33.3% 1/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	75.0% 3/4 • Number of events 7 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	50.0% 2/4 • Number of events 8 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	80.0% 4/5 • Number of events 11 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Investigations Blood bilirubin increased	33.3% 1/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	60.0% 3/5 • Number of events 5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Investigations CPK increased	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	50.0% 2/4 • Number of events 13 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	40.0% 2/5 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Investigations Platelet count decreased	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 7 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Metabolism and nutrition disorders Anorexia	66.7% 2/3 • Number of events 5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 10 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Metabolism and nutrition disorders Hypoalbuminemia	33.3% 1/3 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Metabolism and nutrition disorders Hypokalemia	33.3% 1/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	40.0% 2/5 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	66.7% 2/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Nervous system disorders Dizziness	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Nervous system disorders Headache	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	60.0% 3/5 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Nervous system disorders Paresthesia	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 2/6 • Number of events 6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	60.0% 3/5 • Number of events 5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Nervous system disorders Vasovagal reaction	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 2/6 • Number of events 6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Respiratory, thoracic and mediastinal disorders Dyspnea	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 7 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	66.7% 2/3 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 8 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 12 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	40.0% 2/5 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 12 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	66.7% 2/3 • Number of events 6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 18 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Skin and subcutaneous tissue disorders Rash acneiform	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 2 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	16.7% 1/6 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Vascular disorders Hypertension	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	33.3% 1/3 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 7 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
Skin and subcutaneous tissue disorders Other	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	75.0% 3/4 • Number of events 5 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 14 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.
General disorders Other	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/3 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/4 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	0.00% 0/6 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	25.0% 1/4 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.	20.0% 1/5 • Number of events 1 • AEs were graded and recorded from the trial entry confirmation, at the treatment start cycle 1 day 1, at day 1 of each CCT3833 (28 days) cycles, until the patients' final safety follow up at 30 days after last dose up to 18 months. All cause of mortality is recorded until death or end of trial (36 months). An adverse event (AE) is any untoward, undesired or unplanned occurrence in a patient administered an IMP, a comparator product or an approved drug. An AE can be a sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the CCT3833 or comparator.

Additional Information

PANRAF Trial Manager

The Royal Marsden NHS Foundation Trust

Phone: (+44)2089156666

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place